228 related articles for article (PubMed ID: 2178625)
1. Drug metabolism by leukocytes and its role in drug-induced lupus and other idiosyncratic drug reactions.
Uetrecht J
Crit Rev Toxicol; 1990; 20(4):213-35. PubMed ID: 2178625
[TBL] [Abstract][Full Text] [Related]
2. The role of leukocyte-generated reactive metabolites in the pathogenesis of idiosyncratic drug reactions.
Uetrecht JP
Drug Metab Rev; 1992; 24(3):299-366. PubMed ID: 1628536
[TBL] [Abstract][Full Text] [Related]
3. Metabolism of hydralazine by activated leukocytes: implications for hydralazine induced lupus.
Hofstra AH; Matassa LC; Uetrecht JP
J Rheumatol; 1991 Nov; 18(11):1673-80. PubMed ID: 1664857
[TBL] [Abstract][Full Text] [Related]
4. Metabolism of drugs by activated leukocytes: implications for drug-induced lupus and other drug hypersensitivity reactions.
Uetrecht J
Adv Exp Med Biol; 1991; 283():121-32. PubMed ID: 2068978
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of isoniazid by activated leukocytes. Possible role in drug-induced lupus.
Hofstra AH; Li-Muller SM; Uetrecht JP
Drug Metab Dispos; 1992; 20(2):205-10. PubMed ID: 1352211
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of hypersensitivity reactions: proposed involvement of reactive metabolites generated by activated leukocytes.
Uetrecht J
Trends Pharmacol Sci; 1989 Nov; 10(11):463-7. PubMed ID: 2692259
[TBL] [Abstract][Full Text] [Related]
7. Blood dyscrasias secondary to non-steroidal anti-inflammatory drugs.
Miescher PA
Med Toxicol; 1986; 1 Suppl 1():57-70. PubMed ID: 3547002
[TBL] [Abstract][Full Text] [Related]
8. Peroxidase-mediated bioactivation of hydroxylated metabolites of carbamazepine and phenytoin.
Lu W; Uetrecht JP
Drug Metab Dispos; 2008 Aug; 36(8):1624-36. PubMed ID: 18463199
[TBL] [Abstract][Full Text] [Related]
9. Metabolism of ticlopidine by activated neutrophils: implications for ticlopidine-induced agranulocytosis.
Liu ZC; Uetrecht JP
Drug Metab Dispos; 2000 Jul; 28(7):726-30. PubMed ID: 10859143
[TBL] [Abstract][Full Text] [Related]
10. [Tuberculosis in compromised hosts].
Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
[TBL] [Abstract][Full Text] [Related]
11. Oxidation of a metabolite of indomethacin (Desmethyldeschlorobenzoylindomethacin) to reactive intermediates by activated neutrophils, hypochlorous acid, and the myeloperoxidase system.
Ju C; Uetrecht JP
Drug Metab Dispos; 1998 Jul; 26(7):676-80. PubMed ID: 9660850
[TBL] [Abstract][Full Text] [Related]
12. Drug-induced lupus.
Rubin RL
Toxicology; 2005 Apr; 209(2):135-47. PubMed ID: 15767026
[TBL] [Abstract][Full Text] [Related]
13. N-chlorination of sulfamethoxazole and dapsone by the myeloperoxidase system.
Uetrecht JP; Shear NH; Zahid N
Drug Metab Dispos; 1993; 21(5):830-4. PubMed ID: 7902244
[TBL] [Abstract][Full Text] [Related]
14. Prediction of a new drug's potential to cause idiosyncratic reactions.
Uetrecht J
Curr Opin Drug Discov Devel; 2001 Jan; 4(1):55-9. PubMed ID: 11727323
[TBL] [Abstract][Full Text] [Related]
15. Delayed drug hypersensitivity reactions - new concepts.
Posadas SJ; Pichler WJ
Clin Exp Allergy; 2007 Jul; 37(7):989-99. PubMed ID: 17581192
[TBL] [Abstract][Full Text] [Related]
16. Peroxidase-dependent oxidation of sulfonamides by monocytes and neutrophils from humans and dogs.
Cribb AE; Miller M; Tesoro A; Spielberg SP
Mol Pharmacol; 1990 Nov; 38(5):744-51. PubMed ID: 2172779
[TBL] [Abstract][Full Text] [Related]
17. Comparative metabolism and covalent binding of procainamide by human leukocytes.
Uetrecht J; Sokoluk B
Drug Metab Dispos; 1992; 20(1):120-3. PubMed ID: 1346986
[TBL] [Abstract][Full Text] [Related]
18. The danger hypothesis applied to idiosyncratic drug reactions.
Li J; Uetrecht JP
Handb Exp Pharmacol; 2010; (196):493-509. PubMed ID: 20020274
[TBL] [Abstract][Full Text] [Related]
19. Role of drug metabolism for breaking tolerance and the localization of drug hypersensitivity.
Uetrecht J
Toxicology; 2005 Apr; 209(2):113-8. PubMed ID: 15767022
[TBL] [Abstract][Full Text] [Related]
20. [Free radicals and antioxidants: physiology, human pathology and therapeutic aspects (part II)].
Sahnoun Z; Jamoussi K; Zeghal KM
Therapie; 1998; 53(4):315-39. PubMed ID: 9806002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
